(MAZE) Maze Therapeutics, Common - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.415m USD | Total Return: 153.5% in 12m
Avg Turnover: 13.5M
Qual. Beats: 0
Warnings
Share dilution 23.1% YoY
Interest Coverage Ratio -148.2 is critical
Altman Z'' -7.60 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Maze Therapeutics, Inc. (MAZE) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm specializes in developing small molecule precision medicines, focusing on kidney and metabolic disorders. Its primary pipeline includes MZE829 for APOL1-mediated kidney disease and MZE782 for phenylketonuria, both of which utilize an oral delivery mechanism to improve patient compliance compared to injectable biologics.
The company operates within the high-growth precision medicine sector, where therapies are engineered to target specific genetic drivers of disease. Maze leverages a partnership-heavy business model, maintaining strategic licensing agreements with industry players such as Shionogi & Co. and Neurocrine Biosciences to co-develop and commercialize its research programs. This approach allows clinical-stage firms to mitigate the high capital expenditures typical of drug development while retaining access to specialized manufacturing and distribution networks.
For more detailed insights into the company’s financial health and valuation metrics, consider exploring the data available on ValueRay. Maze Therapeutics continues to advance its lead programs through Phase II trials while expanding its research into neuromuscular targets like Pompe disease and ALS through its UNC13A and ATXN2 programs.
- Phase II clinical trial results for MZE829 determine APOL1 kidney disease program valuation
- Success of Shionogi partnership dictates milestone revenue from MZE001 development for Pompe disease
- Regulatory progression of MZE782 influences competitive positioning in phenylketonuria and chronic kidney disease
- Strategic collaboration milestones from Neurocrine Biosciences impact long-term research and development funding
| Net Income: -122.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.24 > 0.02 and ΔFCF/TA -43.33 > 1.0 |
| NWC/Revenue: 1.79k% < 20% (prev 167.8%; Δ 1.62k% < -1%) |
| CFO/TA -0.29 > 3% & CFO -121.5m > Net Income -122.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 17.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (53.9m) vs 12m ago 23.06% < -2% |
| Gross Margin: 87.98% > 18% (prev 0.99%; Δ 8.70k% > 0.5%) |
| Asset Turnover: 5.32% > 50% (prev 50.32%; Δ -45.01% > 0%) |
| Interest Coverage Ratio: -148.2 > 6 (EBITDA TTM -126.2m / Interest Expense TTM 866k) |
| A: 0.85 (Total Current Assets 379.8m - Total Current Liabilities 21.2m) / Total Assets 419.7m |
| B: -1.22 (Retained Earnings -513.8m / Total Assets 419.7m) |
| C: -0.34 (EBIT TTM -128.4m / Avg Total Assets 376.3m) |
| D: -6.59 (Book Value of Equity -513.8m / Total Liabilities 78.0m) |
| Altman-Z'' = -7.60 = D |
As of May 24, 2026, the stock is trading at USD 25.75 with a total of 431,767 shares traded.
Over the past week, the price has changed by +0.86%,
over one month by -2.72%,
over three months by -43.39% and
over the past year by +153.49%.
Maze Therapeutics, Common has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy MAZE.
- StrongBuy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 63 | 144.7% |
P/S = 70.7312
P/B = 4.0514
Revenue TTM = 20.0m USD
EBIT TTM = -128.4m USD
EBITDA TTM = -126.2m USD
Long Term Debt = 56.4m USD (estimated: total debt 61.2m - short term 4.84m)
Short Term Debt = 4.84m USD (from shortTermDebt, last quarter)
Debt = 84.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 23.3m
Net Debt = -267.9m USD (calculated: Debt 84.5m - CCE 352.4m)
Enterprise Value = 1.15b USD (1.41b + Debt 84.5m - CCE 352.4m)
Interest Coverage Ratio = -148.2 (Ebit TTM -128.4m / Interest Expense TTM 866k)
EV/FCF = -11.39x (Enterprise Value 1.15b / FCF TTM -100.7m)
FCF Yield = -8.78% (FCF TTM -100.7m / Enterprise Value 1.15b)
FCF Margin = -503.4% (FCF TTM -100.7m / Revenue TTM 20.0m)
Net Margin = -612.7% (Net Income TTM -122.5m / Revenue TTM 20.0m)
Gross Margin = 87.98% ((Revenue TTM 20.0m - Cost of Revenue TTM 2.40m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 2.73 (Enterprise Value 1.15b / Total Assets 419.7m)
Interest Expense / Debt = 1.02% (Interest Expense 866k / Debt 84.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -101.4m (EBIT -128.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 15.04 (Total Current Assets 379.8m / Total Current Liabilities 25.2m)
Debt / Equity = 0.25 (Debt 84.5m / totalStockholderEquity, last quarter 341.7m)
Debt / EBITDA = 2.12 (negative EBITDA) (Net Debt -267.9m / EBITDA -126.2m)
Debt / FCF = 2.66 (negative FCF - burning cash) (Net Debt -267.9m / FCF TTM -100.7m)
Total Stockholder Equity = 334.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -32.57% (Net Income -122.5m / Total Assets 419.7m)
RoE = -14.44% (Net Income TTM -122.5m / Total Stockholder Equity 848.3m)
RoCE = -14.19% (EBIT -128.4m / Capital Employed (Equity 848.3m + L.T.Debt 56.4m))
RoIC = -25.15% (negative operating profit) (NOPAT -101.4m / Invested Capital 403.3m)
WACC = 9.33% (E(1.41b)/V(1.50b) * Re(9.84%) + D(84.5m)/V(1.50b) * Rd(1.02%) * (1-Tc(0.21)))
Discount Rate = 9.84% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 43.19 | Cagr: 9.68%
[DCF] Fair Price = unknown (Cash Flow -100.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.00 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.69 | Chg30d=+10.01% | Revisions=+11% | Analysts=7
EPS next Quarter (2026-09-30): EPS=-0.75 | Chg30d=+1.50% | Revisions=+11% | Analysts=7
EPS current Year (2026-12-31): EPS=-2.67 | Chg30d=+4.17% | Revisions=-11% | GrowthEPS=+12.6% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.24 | Chg30d=+6.97% | Revisions=+25% | GrowthEPS=-21.6% | GrowthRev=-45.9%
[Analyst] Revisions Ratio: +25%